ClinicalTrials.gg
CompletedNCT03928262Updated Aug 30, 2019

Pharmacokinetic Study of Benralizumab in Healthy Chinese Subjects

A Phase 1 interventional study of Benralizumab in Healthy Subjects, sponsored by AstraZeneca. Completed at 1 site in Hong Kong. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-30.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a Phase 1, randomized, single-blind study in healthy Chinese subjects at single dose administration of benralizumab: Treatment 1, Treatment 2 and Treatment 3. The study design allows an assessment of 3 doses with safety monitoring and PK sampling to evaluate the safety, tolerability and PK profile of benralizumab.

Read the detailed description

This study will be conducted at 1 study center in Hong Kong. Approximately 36 healthy Chinese male and female subjects, aged 18 to 45 inclusive, will be randomized in a 1:1:1 ratio to receive a single SC administration of benralizumab: Treatment 1, Treatment 2 and Treatment 3 (12 subjects per group). Each subject will participate in only 1 treatment group. Approximately 8-12 evaluable subjects in each group that met specific non-compartmental analysis (NCA) criteria are required to ensure eligible AUC0-∞ calculation. The total length of the study for each subject is up to 117 days (28 days of screening and 85+/- 4 days of further study visits).

02

Conditions studied

  • Healthy Subjects

Keywords

  • Pharmacokinetics
  • Safety
  • Tolerability
  • Benralizumab
  • Healthy Chinese subjects
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must be willing and able to give written by signing an IRB/IEC approved Informed Consent Form (ICF) and follow the restrictions and procedures outlined for the study.
  2. Healthy adult males or females as determined by medical history, physical examination, and laboratory tests. Subjects age between 18 to 45 years old (inclusive) at the time of signing informed consent. Subject is a Han Chinese who were born in China (including Hong Kong) with Han Chinese parents and grandparents who were born in China (including Hong Kong)
  3. Have a (BMI) between 19 and 24 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg.
  4. Medically healthy subjects with clinically insignificant screening results (e.g., laboratory profiles, medical histories, [ECGs], physical examination). must be greater than the lower limit of normal. A 12-lead ECG with >340 msec and \<450 msec.
  5. Women of (WOCBP) must have a negative urine pregnancy test prior to administration of the IP and use an effective form of (confirmed by the Investigator or designee). Highly effective forms of birth control include: true sexual abstinence, a vasectomised sexual partner, Implanon, female sterilization by tubal occlusion, any effective IUD Intrauterine device/IUS Ievonorgestrel Intrauterine system, Depo-Provera™ injections, oral contraceptive, and Evra Patch ™ or Nuvaring™. WOCBP must agree to use an effective method of birth control, as defined above, from enrolment, throughout the study duration and within 16 weeks (5 half-lives or longer) after the dosing and have negative serum or urine pregnancy test result on Visit 1 and Visit 2.
  6. Women of non-childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are . Women will be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatment and follicle stimulating hormone (FSH) levels in the postmenopausal range.
  7. Male subjects should be willing to use condoms, in association with another method of contraception, from the day of the first dosing until 16 weeks (5 half-lives or longer) after the dosing.

Exclusion criteria

Exclusion Criteria:

  1. Any subject with a history of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, or neurological disorder that is capable of altering the metabolism or elimination of drugs or that constitutes a risk factor when taking the study medication.
  2. Any subject with a documented history of disorders of the immune system at any time.
  3. A helminth parasitic infection diagnosed within 24 weeks prior to the date is obtained that has not been treated with or has failed to respond to standard of care therapy.
  4. , current or within the past 5 years, except for adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than 1 year prior to Visit 1.
  5. Any subject with a relevant deviation from normal in physical examination, electrocardiography, or clinical laboratory tests, as determined by the Principal Investigator.
  6. Any clinical significant findings off Chest x-rays or CT image. If a chest X-ray or CT has not been performed within 6 months prior to screening visit, a chest X-ray must be performed before the IP administration.
  7. (ALT) or aspartate aminotransferase (AST) level > the (ULN).
  8. Positive result on screening for serum surface antigen, or antibody. Subjects with a history of hepatitis B vaccination without history of hepatitis B are allowed to enroll. A history of known immunodeficiency disorder including a positive (HIV) test.
  9. Any subject with any condition resulting in an increased eosinophil count at screening.
  10. Any condition requiring the regular use of any medication.
  11. Any subject requiring a prescription medication, other than . Subjects taking nonprescription medications must be willing and able to refrain from their use during the inpatient period of the study.
  12. Use of medication (including but not limited to: methotrexate, troleandomycin, cyclosporine, azathioprine, systemic for condition other than short course for nasal polyps, or any experimental anti-inflammatory therapy) within 3 months prior to the date informed consent is obtained, and during the study period.
  13. Receipt of any marketed or biologic (monoclonal or polyclonal antibody) within 4 months or 5 half-lives prior to the date informed consent, is obtained, whichever is longer, and during the study period. E.g. Previous receipt of mepolizumab, reslizumab, dupilumab, or benralizumab.
  14. Receipt of immunoglobulin or blood products within 30 days prior to the date informed consent is obtained.
  15. Receipt of 30 days prior to the date of informed consent.
  16. Any subject with known sensitivity to any constituent of benralizumab or any other IL-5 receptor antagonist. History of anaphylaxis to any biologic therapy.
  17. Any subject who has participated in any other study of an IP within either 30 days or 5 half-lives (if known) prior to Visit 1, whichever is longer.
  18. Current evidence of drug abuse or history of drug abuse within 1 year of randomization, and/or positive results of drug screen and alcohol test at screening and at Day -1.
  19. Subjects who have an average weekly alcohol intake that exceeds 21 units per week or subjects unwilling to stop alcohol consumption for the duration of the study (1 unit=12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits).
  20. Smoker of more than 5 cigarettes/day or equivalent use of nicotine products during the previous 3 months from the day of screening.
  21. Currently pregnant, breastfeeding or lactating women.
  22. Any subject who plans to undergo elective surgery within 4 weeks before Visit 3 (Day 1) through the end of the study (Day 85).
  23. Any subject who has donated blood or in any other way had a loss of blood volume greater than 400 mL within 30 days before beginning the study IP administration.
  24. Any subject who is unwilling to reside in the clinic during the study period or is unwilling to cooperate fully with the Principal Investigator or designee.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Benralizumab - Subcutaneous administration of Dose 1

    Benralizumab single dose administration subcutaneously

    Biological: Benralizumab

  • Experimental
    Benralizumab - Subcutaneous administration of Dose 2

    Benralizumab single dose administration subcutaneously

    Biological: Benralizumab

  • Experimental
    Benralizumab - Subcutaneous administration of Dose 3

    Benralizumab single dose administration subcutaneously

    Biological: Benralizumab

Interventions

  • BiologicalBenralizumab

    Treatment 1: Benralizumab single dose, Treatment 2: Benralizumab single dose and Treatment 3: Benralizumab single dose subcutaneously administration on 36 healthy Chinese male and female subjects in 1:1:1 ratio.

06

What researchers measure

Primary outcomes

  1. Number of subjects with Adverse events (AEs) and serious adverse events (SAEs)

    The number and percentage of subjects with treatment-emergent AE/SAE/AE by severity/drug-related AE/drug-related SAE/death in each dose level group and overall. AE/SAE will be displayed by MedDRA SOC and/or PT.

    Time frame: Day (-1) to Day 85

  2. Safety as determined by abnormality in haematology

    Measurement of red blood cell count, white blood cell count, haemoglobin and platelets

    Time frame: Day (-1) to Day 85

  3. Safety as determined by abnormality in clinical chemistry

    Measurement of kidney function (e.g.urea ,creatinine, Uric acid), liver function(ALP, ALT, AST, albumin, total bilirubin), lipid profile(total cholesterol, triglycerides), potassium.

    Time frame: Day (-1) to Day 85

  4. Safety as determined by abnormality in urinalysis

    Measurement of glucose, ketones, leukocytes, blood and protein

    Time frame: Day (-1) to Day 85

  5. Safety as determined by evaluation of blood pressure in mmHg

    Measurement of blood pressure (systolic and diastolic in mmHg)

    Time frame: Day (-1) to Day 85

  6. Safety as determined by evaluation of Pulse rate in beats per minute

    Measurement of Pulse rate in beats per minute

    Time frame: Day (-1) to Day 85

  7. Safety as determined by evaluation of body temperature in degree Celsius

    Measurement of body temperature in degree Celsius

    Time frame: Day (-1) to Day 85

  8. Safety as determined by analysis of 12-lead ECG variables: heart rate (beats per minute)

    The ECG variables will be summarized by absolute value at each visit by treatment group, together with the corresponding changes from baseline.

    Time frame: Day (-1) to Day 85

  9. Safety as determined by analysis of 12-lead ECG variables: PR, QRS, QT and QTcF (milliseconds)

    The ECG variables will be summarized by absolute value at each visit by treatment group, together with the corresponding changes from baseline.

    Time frame: Day (-1) to Day 85

Secondary outcomes

  1. Maximum observed concentration (Cmax)

    To assess the Pharmacokinetic profile of Subcutaneously administration of benralizumab in healthy Chinese subjects.

    Time frame: Blood samples will be collected from Day 1 (1 hour prior to administration of IP) and on Day 2, Day 4, Day 5, Day 6, Day 8, Day 15, Day 29, Day 43, Day 57 and Day 85

  2. Time to maximum observed concentration (tmax)

    To assess the Pharmacokinetic profile of subcutaneously administration of benralizumab in healthy Chinese subjects.

    Time frame: Blood samples will be collected from Day 1 (1 hour prior to administration of IP) and on Day 2, Day 4, Day 5, Day 6, Day 8, Day 15, Day 29, Day 43, Day 57 and Day 85.

  3. Area under the concentration-time curve from 0 to the last measurable time point (AUC0-t)

    To assess the Pharmacokinetic profile of subcutaneously administration benralizumab in healthy Chinese subjects.

    Time frame: Blood samples will be collected from Day 1 (1 hour prior to administration of IP) and on Day 2, Day 4, Day 5, Day 6, Day 8, Day 15, Day 29, Day 43, Day 57 and Day 85.

  4. Area under the concentration-time curve from 0 to infinity (AUC0-∞)

    To assess the Pharmacokinetic profile of subcutaneously administration benralizumab in healthy Chinese subjects.

    Time frame: Blood samples will be collected from Day 1 (1 hour prior to administration of IP) and on Day 2, Day 4, Day 5, Day 6, Day 8, Day 15, Day 29, Day 43, Day 57 and Day 85.

  5. Apparent clearance (CL/F)

    To assess the Pharmacokinetic profile of subcutaneously administration benralizumab in healthy Chinese subjects.

    Time frame: Blood samples will be collected from Day 1 (1 hour prior to administration of IP) and on Day 2, Day 4, Day 5, Day 6, Day 8, Day 15, Day 29, Day 43, Day 57 and Day 85.

  6. Apparent volume of distribution at terminal phase (Vz/F)

    To assess the Pharmacokinetic profile of subcutaneously administration benralizumab in healthy Chinese subjects.

    Time frame: Blood samples will be collected from Day 1 (1 hour prior to administration of IP) and on Day 2, Day 4, Day 5, Day 6, Day 8, Day 15, Day 29, Day 43, Day 57 and Day 85.

  7. Time for concentration to decrease by 50% (concentration half-life) (t1/2)

    To assess the Pharmacokinetic profile of subcutaneously administration benralizumab in healthy Chinese subjects.

    Time frame: Blood samples will be collected from Day 1 (1 hour prior to administration of IP) and on Day 2, Day 4, Day 5, Day 6, Day 8, Day 15, Day 29, Day 43, Day 57 and Day 85.

  8. Anti-drug antibody (ADA) as determined by evaluation of ADA positive percentage and ADA negative percentage

    To assess the immunogenicity of benralizumab.

    Time frame: Blood samples will be collected from Day 1 (1 hour prior to administration of IP) and on Day 29, Day 57 and Day 85.

  9. All ADA positive samples will be tested for neutralizing antibodies (nAb). nAb as determined by evaluation of nAb positive percentage

    To assess the immunogenicity of benralizumab.

    Time frame: Blood samples will be collected from Day 1 (1 hour prior to administration of IP) and on Day 29, Day 57 and Day 85.

07

Study locations

1 site
  • Research Site
    Hong Kong, Hong Kong
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Aug 2019, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2019
First posted
Apr 26, 2019
StartActual
Apr 2, 2019
Primary completionActual
Aug 12, 2019
CompletionActual
Aug 12, 2019
Last update
Aug 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03928262
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 26, 2019
Start date
Apr 2, 2019
Primary completion
Aug 12, 2019
Completion
Aug 12, 2019
Last update
Aug 30, 2019

Study contacts

Tsang Tommy Cheung, MBBS
principal investigator · HKU Phase 1 Clinical Trials Centre, 2/F, Block K, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion